Nuveen LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Nuveen LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 71.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,010,517 shares of the biopharmaceutical company’s stock after buying an additional 835,240 shares during the quarter. Nuveen LLC’s holdings in Regeneron Pharmaceuticals were worth $1,551,858,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Xponance LLC lifted its position in Regeneron Pharmaceuticals by 2.4% during the fourth quarter. Xponance LLC now owns 15,636 shares of the biopharmaceutical company’s stock worth $12,069,000 after buying an additional 362 shares in the last quarter. Keel Point LLC lifted its position in Regeneron Pharmaceuticals by 21.5% during the fourth quarter. Keel Point LLC now owns 543 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 96 shares in the last quarter. IFM Investors Pty Ltd lifted its position in Regeneron Pharmaceuticals by 0.4% during the fourth quarter. IFM Investors Pty Ltd now owns 20,738 shares of the biopharmaceutical company’s stock worth $16,007,000 after buying an additional 75 shares in the last quarter. SmartHarvest Portfolios LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $323,000. Finally, Picton Mahoney Asset Management lifted its position in Regeneron Pharmaceuticals by 89.2% during the fourth quarter. Picton Mahoney Asset Management now owns 15,584 shares of the biopharmaceutical company’s stock worth $12,029,000 after buying an additional 7,349 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $611.48 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $503.25 and a 52 week high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $64.65 billion, a P/E ratio of 14.90, a P/E/G ratio of 1.32 and a beta of 0.25. The stock’s fifty day moving average is $695.41 and its two-hundred day moving average is $739.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the previous year, the business earned $8.22 earnings per share. The company’s revenue for the quarter was up 19.0% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Investor-focused writeups highlighted a bullish thesis on Regeneron, pointing to valuation metrics that look reasonable for a large-cap biotech and reinforcing the view that the stock may be attractive for long-term buyers. Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy Now?
• Positive Sentiment: Regeneron-backed Parabilis Medicines completed a record-setting biotech IPO, and Regeneron also participated in a $75 million private placement, which could be viewed as a strategic investment in an emerging drug developer. Parabilis Medicines, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock at $20.00 per Share
• Neutral Sentiment: Regeneron announced a clinical-study update testing weekly Praluent dosing in a cholesterol trial; investors will likely watch for any sign the program could support future label expansion or demand, but this is still an early-stage study update. Regeneron Tests Weekly Praluent Dosing in New Cholesterol Study: What Investors Should Watch
• Negative Sentiment: Pomerantz LLP and Schall Law Firm both disclosed investigations into possible claims involving Regeneron, which adds legal overhang and could weigh on sentiment if the probes broaden or lead to litigation. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
• Negative Sentiment: Sensorion said it is shifting away from a hearing-loss gene therapy partly because the development environment has changed due to Regeneron competition, underscoring that REGN’s pipeline and competitive position can pressure rivals in specific therapeutic areas. Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Barclays reduced their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $800.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Finally, Truist Financial reduced their target price on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $792.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.